LNTH
Lantheus Holdings, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$100.25
−0.14%Price chart
Aug 12Aug 17Aug 20Aug 25Aug 28Sep 2Sep 8Sep 11
ValuationView details →
P/E (Fwd)
17.8x
EV/EBITDA
14.1x
Market Cap
$6.55B
MomentumView details →
1D Return
−0.14%
YTD Return
+50.97%
RSI (14)
45.0
ValuationView details →
P/E (Fwd)
17.8x
EV/EBITDA
14.1x
Market Cap
$6.55B
RSI (14)
45.0
MomentumView details →
1D Return
−0.14%
YTD Return
+50.97%
SummaryUpdated Jun 1, 2026
Lantheus Holdings, Inc. (NASDAQ:LNTH) is a specialized pharmaceutical company founded in 1956 and headquartered in North Billerica, Massachusetts. The company develops, manufactures, and commercializes diagnostic and therapeutic radiopharmaceuticals that assist clinicians in diagnosing and treating heart disease, cancer, and other conditions. Originally focused on traditional nuclear medicine products, Lantheus has transformed into a leading player in the rapidly growing radiopharmaceutical oncology market, particularly through its blockbuster PSMA PET imaging agent PYLARIFY, which became the first radiopharmaceutical to exceed $1 billion in annual sales.
Similar companies
Latest newsMore news →
Kahn Swick & Foti, LLC is investigating the proposed sale of Lantheus Holdings, Inc. to Curium US Holdings LLC, under which Lantheus shareholders would receive $102.50 per share in cash plus non-transferable Contingent Value Rights worth up to $12.00 per share.3d agoLantheus Alpha Therapy, LLC, a director and 10% owner of Perspective Therapeutics, sold 42,129 shares of common stock for $131,219 on September 2, 2026.9d agoHalper Sadeh LLC announced it is investigating the sale of Lantheus Holdings, Inc. to Curium US Holdings LLC for $102.50 per share in cash plus contingent value rights of up to $12.00 per share.16d ago